Deep Tech Startups

Nova (洛启生物 / Novamab) develops VHH-based (nanobody) therapeutics using its in-house discovery and molecular engineering platform, covering antibody library construction, high-throughput screening, affinity maturation, humanization, and developability assessment. The company targets applications such as local delivery, oral administration, and multispecific molecule design for drug development.

1 investor

Novilla develops localized medicines designed with proprietary chemical-thermodynamics machine learning algorithms, delivering drugs that act at the site of disease while minimizing systemic exposure and side effects. The company focuses on pain therapeutics, aiming to provide effective treatments without the addiction risks associated with opioids.

1 investor

Novilytic develops a simplified analytical testing system using a single HPLC instrument with fluorescence detection and proprietary Proteometer Kit to replace multiple instruments and personnel traditionally required for R&D analytical work in chemistry.

1 investor

Novity provides predictive maintenance AI technology for industrial manufacturers to prevent unplanned downtime and improve production reliability. The company combines physics models with machine learning to forecast the health of manufacturing assets.

1 investor

Novo Protein supplies GMP-grade mRNA enzymes, reagents, and diagnostic materials for biopharmaceutical research and production, including reagents for in vitro transcription, molecular diagnostics, gene editing, and immunoassay development.

1 investor

NovoPyxis applies mathematics and physics principles, including knot theory and fluid dynamics, to drug design and delivery, predicting protein structures of uncrystallized targets and designing peptide agonists. Its work includes a cardiomyopathy drug candidate and a transdermal device for delivering large-molecule drugs into skin.

1 investor

NovoViz develops patented computational single-photon sensors for imaging applications. The company provides both proprietary sensor technology and expert design services tailored to customer requirements across various industries.

1 investor

NOVUSON develops biomedical instrumentation and medical devices, serving healthcare organizations and clinical environments. The company focuses on innovative medical technology across biomechanics, tissue engineering, and surgical device platforms.

1 investor

NovusTX Devices develops therapeutic ultrasound technology for clinical medical applications, particularly focusing on minimally invasive brain therapies using HIFU (high-intensity focused ultrasound). The company emerged from research collaboration at the Thunder Bay Regional Health Research Institute and the University of Calgary.

1 investor

Noxilizer develops a low-temperature, low-pressure nitrogen dioxide (NO₂) sterilization technology used to sterilize prefilled syringes, biologic drug-device combination products, and other sensitive medical products as an alternative to ethylene oxide. It serves pharmaceutical companies, biotech firms, and medical device manufacturers through lab services, R&D studies, regulatory support, IP licensing, and planned contract sterilization.

1 investor

Noxon develops OCIAN, a non-invasive, skin-worn muscle-computer interface that decodes myoelectric signals and modulates muscle and nerve activity to track neuromuscular health and enable movement coordination and interface control. The system pairs a wearable electronic unit with a cloud platform ("OCIAN Hub") that transfers bidirectional signals between muscles and software.

1 investor

Nordic Science Investments is an early-stage venture capital fund that invests in science-based startups and university spinouts across the Nordic region, with a focus on deeptech, health tech, and life sciences. The fund works with leading regional universities to commercialize frontier research and tackle global challenges.

1 investor

NSLComm develops and operates satellite communication systems and networks. The company brings together expertise in space technology development and satellite operations serving commercial and defense markets.

1 investor

ns/tx industries develops a plant-based food scaffolding and manufacturing platform that recreates the muscle fiber, fat, and connective-tissue structure of real meat and seafood, producing whole-cut, ground, breaded, and smoked alternatives for beef, salmon, and pork. It operates a vertically integrated, SQF-certified production facility in Toronto and serves brand partners through contract manufacturing, custom formulation, and its own consumer brand, New School Foods.

1 investor

NTI Fund is a Russian government institution supporting the National Technological Initiative, which develops emerging technology markets and sectors critical to technological leadership and sovereignty. The fund conducts market research, identifies promising technologies and products from Russian producers, organizes technology competitions, and supports unmanned aviation systems and digital health initiatives.

1 investor

NTWIST develops AI-powered software and agentic AI systems that help mining and manufacturing teams optimize industrial operations, connecting to SCADA, MES, ERP, and PLC systems to support decisions from the pit and shop floor to the boardroom. Its products cover predictive modeling, real-time optimization, and intelligent automation for industrial operators, planners, and executives.

1 investor

NUBURU develops high-power industrial blue lasers for welding copper, aluminum, and other metals, as well as additive manufacturing and 3D printing. Its BL and BL-F product lines target manufacturers in energy storage, e-mobility, aerospace, healthcare, and electronics packaging.

1 investor

NucleoTech engineers BrainPortal carrier proteins that attach to therapeutic antibodies and oligonucleotides and transport them across the blood-brain barrier non-invasively, using a direct in vivo screening platform to test many candidates simultaneously. It advances internal CNS therapeutics and licenses its carriers to pharma and biotech partners.

1 investor

Nugen builds domain-aligned AI models designed for reliable performance in complex professional fields such as legal and financial services, where general-purpose AI models fall short. It offers enterprise-grade deployment options (cloud, virtual private cloud, or on-premises) with secure connectors and APIs to integrate into existing enterprise systems.

1 investor

Nula Therapeutics develops targeted small-molecule medicines that correct how the nuclear envelope regulates gene expression and cellular function. The company focuses on treating age-related diseases including metabolic dysfunction, neurodegeneration, and cancer, and on extending healthspan.

1 investor

N0 Labs develops an open environment simulation platform that enables robotics and AI teams to accelerate robot development and testing by providing tools for perception and action systems.

1 investor

Numascale designs node controller chips that enable servers to scale from 8 to 32 CPUs as cache-coherent shared memory systems, targeting enterprise high-performance computing workloads. Their UNC5 product powers scale-up servers from manufacturers including Eviden, Dell, and Hitachi for applications like SAP HANA and OLAP analytics.

1 investor

Numb Corp develops TRPV1-targeted, botulinum-derived biologics that selectively enter sensory neurons to produce prolonged local inhibition of neurotransmission, aiming to deliver durable regional pain control. Its therapeutics are designed to be locally administered to control pain near its source while avoiding the systemic exposure associated with conventional pain medicines, including opioids.

1 investor

Numenos builds patient-centric biological world models that learn from individual patient data across all diseases to discover the causal mechanisms underlying human biology. The platform applies machine learning to biology with the aim of enabling individualized treatments.

1 investor